Menu Search
Equities

Venture Life Group PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
17V:STU

Venture Life Group PLC

Actions
  • Price (EUR)0.75
  • Today's Change-0.02 / -2.60%
  • Shares traded0.00
  • 1 Year change+71.23%
  • Beta0.5837
Data delayed at least 15 minutes, as of Feb 16 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Venture Life Group PLC is a United Kingdom-based consumer self-care company. The Company is focused on product development and commercialization within the global consumer healthcare sector. Its product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, and Gelclair and Pomi-T for oncology support products that provide symptomatic relief for some of the side effects associated with cancer and its treatment. Its products include Baby Earol, EarolSwim, Earol, Glucogel, and Lift Glucose. The products, which are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples and are sold in over 90 countries worldwide. In the United Kingdom and The Netherlands, products are supplied direct by the Company to retailers, elsewhere they are supplied by its international distribution partners.

  • Revenue in GBP (TTM)18.53m
  • Net income in GBP-295.00k
  • Incorporated2005
  • Employees58.00
  • Location
    Venture Life Group PLCUnit 12, The Courtyard, Eastern RoadBRACKNELL RG12 2XBUnited KingdomGBR
  • Phone+44 134 457 8004
  • Fax+44 134 474 2970
  • Websitehttps://www.venture-life.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.